Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Closed 09-23 16:00:00 EDT

36.82

-1.40

-3.66%

盘后36.82

+0.000.00%

19:30 EDT

High38.47	Low36.78	Vol9.27M
Open38.00	D1 Closing38.22	Amplitude4.42%
Mkt Cap26.60B	Tradable Cap21.39B	Total Shares722.41M
T/O344.69M	T/O Rate1.60%	Tradable Shares581.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":36.82,"timestamp":1790193600000,"preClose":38.22,"halted":0,"volume":9272934,"hourTrading":{"tag":"盘后","latestPrice":36.82,"preClose":36.82,"latestTime":"19:30 EDT","volume":1602899,"amount":59018829.65,"timestamp":1790206202500,"change":0,"changeRate":0,"amplitude":0.001901},"delay":0,"changeRate":-0.0366300366300366,"floatShares":581000000,"shares":722406273,"eps":-0.47,"marketStatus":"Closed","change":-1.4,"latestTime":"09-23 16:00:00 EDT","open":38,"high":38.47,"low":36.78,"amount":344687567.97024,"amplitude":0.044218,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.47,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790236800000},"marketStatusCode":5,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":38.22,"preHourTrading":{"tag":"盘前","latestPrice":37.84,"preClose":38.22,"latestTime":"08:54 EDT","volume":5335,"amount":198218.68132,"timestamp":1790168091808,"change":-0.38,"changeRate":-0.009942,"amplitude":0.0991},"postHourTrading":{"tag":"盘后","latestPrice":36.82,"preClose":36.82,"latestTime":"19:30 EDT","volume":1602899,"amount":59018829.65,"timestamp":1790206202500,"change":0,"changeRate":0,"amplitude":0.001901},"volumeRatio":0.794471,"impliedVol":0.3392,"impliedVolPercentile":0.2231},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"2669438437","title":"Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438437?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:20","pubTimestamp":1790184011,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Er...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","PTH","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486413","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486413?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168425,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  slightly declining and the iShares Biotechnology ETF  inactive.Roivant Sciences  said its Immunovant  subsidiary plans to stop development of IMVT-1402 in cutaneous lupus erythematosus after a proof-of-concept study failed to achieve statistical significance on the primary endpoint. Shares of Immunovant and Roivant were down 6.1% and 1%, respectively, pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","XBI","IBB","XLV","BK4581","HCSG","BK4585","ROIV","BK4588","IMVT","LU0128526141.USD","BK4139","PTH","LU0029874061.USD","BK4137","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669372486","title":"Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669372486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669372486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:48","pubTimestamp":1790167737,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movements, world markets' overview, and corporate stock movements.)US equity futures were slightly lower pre-bell Wednesday as traders awaited development","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONC","QTUP","LU1670627923.USD","LU1366192091.USD","IONQ","PTH","WQTM","CQTM","BK4591","BK4141","LU1670628061.USD","IONL","BK4168","BK4139","BK4517","BK4566","IONX","BK4007","BK4588","IONZ","CART","BK4113","IOYY","RCL","BK4602","CARX","SLX","BK4142","IMVT","LU0300736062.USD","BK4585","ROIV","WNDR","LU0300736492.USD","COAL","BHP","BK4170","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669048537","title":"Roivant Sciences price target raised to $41 from $37.50 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669048537","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669048537?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:15","pubTimestamp":1790165711,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and keeps a Neutral rating on the shares after h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ROIV","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483473","title":"Immunovant Falls After Lupus Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483473?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165052,"startTime":"0","endTime":"0","summary":"BUZZ-Immunovant falls after lupus drug setback** Shares of biotech firm ImmunovantIMVT.Ofall 4.5% to $35.6 premarket** Stock set to open at its lowest level in over three months, if losses hold** Co p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","PTH","BK4585","BK4588","ROIV","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669269100","title":"Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2669269100","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669269100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:05","pubTimestamp":1790161507,"startTime":"0","endTime":"0","summary":"Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLERoivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL5xYLBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","NDAQ","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3D17.EUR","BK4007","BK4585","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","SG9999014013.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","IE00BQXX3F31.USD","BCDF","ROIV","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669676100","title":"Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669676100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669676100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100988","title":"Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100988?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","PTH","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669006461","title":"Roivant Sciences - All Other Clinical Development Timelines Remain on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2669006461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669006461?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PTH","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668928863","title":"Roivant Sciences Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928863","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668928863?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:15","pubTimestamp":1789730117,"startTime":"0","endTime":"0","summary":"Roivant Sciences holds annual shareholder meetingRoivant Sciences held its annual general meeting on Sept. 16, 2026.Shareholders backed the reappointment of Ernst & Young LLP as independent auditor fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL5J39Jd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PTH","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668990118","title":"Roivant Sciences Director Meghan FitzGerald Reports $203,159 Common Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2668990118","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668990118?lang=en_us&edition=fundamental","pubTime":"2026-09-18 06:42","pubTimestamp":1789684974,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Meghan FitzGerald reports $203,159 common share saleDirector Meghan FitzGerald sold 5,112 Roivant Sciences common shares on Sep. 15, 2026.Sales priced at USD 39.68 per share ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL2fxFl6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Director Meghan FitzGerald Reports $203,159 Common Share Sale","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668961223","title":"Stifel Nicolaus Initiates Roivant Sciences With Buy Rating, $51 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2668961223","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668961223?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:40","pubTimestamp":1789645253,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus Initiates Roivant Sciences With Buy Rating, $51 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTH","ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668782966","title":"Roivant Sciences Ltd : Stifel Initiates Coverage with Buy Rating; Target Price $51","url":"https://stock-news.laohu8.com/highlight/detail?id=2668782966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668782966?lang=en_us&edition=fundamental","pubTime":"2026-09-17 18:45","pubTimestamp":1789641905,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nFWN4590HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668966903","title":"Roivant Sciences Price Target Announced at $51.00/Share by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2668966903","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668966903?lang=en_us&edition=fundamental","pubTime":"2026-09-17 18:34","pubTimestamp":1789641240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668993375","title":"Roivant Sciences initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2668993375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668993375?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:15","pubTimestamp":1789589720,"startTime":"0","endTime":"0","summary":"Stifel initiated coverage of Roivant Sciences (ROIV) with a Buy rating and $51 price target The company offers a “compelling multi-asset story with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FLSP","ROIV","TBFC","BAMO","TCTL","LEXI","PLGI","USAF","AOR","RULE","PTH","GDMA","MDAA","QIS","BK4007","ASGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667649179","title":"Roivant Sciences Ltd : Leerink Partners Raises Target Price to $52 from $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2667649179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667649179?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:55","pubTimestamp":1789469735,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN45707O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466962","title":"Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466962?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:11","pubTimestamp":1789391469,"startTime":"0","endTime":"0","summary":"Bellevue flags US healthcare innovation as driving fresh investment opportunitiesBellevue Group AG flagged patient-outcome innovation as a key driver of healthcare investment opportunities from recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL8lm3Sh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0433182093.SGD","LU0162691827.USD","LU1201861165.SGD","LU0006061336.USD","ROIV","LU0985489474.SGD","LU1854104046.USD","BK4139","LU0477156797.USD","BK4007","LU0289739343.SGD","LU1854103824.USD","LU1894683348.USD","LU0511384066.AUD","LU0072461881.USD","LU1894683264.USD","BDX","LU0130103400.USD","LU1699723380.USD","LU0985320562.USD","UTHR","BK4585","BK4082","LU0648000940.SGD","LU1489326972.SGD","LU1059921491.USD","LU0289961442.SGD","LQDA","BK4588","LU0878866978.SGD","LU0068578508.USD","LU0130518102.USD","LU0266013472.USD","LU1150488135.SGD","IHI","LU1150488218.USD","LU1571399168.USD","IE00BFXG1179.USD","BK4532","BK4504","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512383","title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512383","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512383?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:01","pubTimestamp":1789088474,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Meghan FitzGerald disposes of USD 798,000 in common sharesRoivant director Meghan FitzGerald exercised stock options for 20,000 common shares at USD 8.8 on Sept. 8.She sold 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL33g4Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666041535","title":"Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2666041535","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666041535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374542","title":"U.S. Stocks on the MOVE-Best Buy, Peloton, Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374542","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374542?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:36","pubTimestamp":1788889011,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Best Buy, Peloton, AppleSeptember 8 (Reuters)-The major U.S. stock indexes edged lower on Tuesday as fresh hostilities in the Middle East pushed oil prices higher, while m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL6N4500HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","PJP","QNT","ALV","QCOM","COHH","PHVS","NATO","ABM","SMHX","P","AAPU","EFSI","DAMD","CQTM","BHVN","QCMD","RGTI","SHAK","SPTE","ROM","RPRX","COHX","HWM","ROIV","IONQ","AMD","BE","INFQ","LITE","ILMN","IONS","COHR","IONX","INTC","UNFI","SAAPLmain","AMGN","SEI","MACW.SI","AAPL","QBTS","BSX","CHRW","SRPT","DYN","SINTCmain","MTB","NTLA","TTXU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0324},{"period":"1month","weight":0.0529},{"period":"3month","weight":0.1238},{"period":"6month","weight":0.3974},{"period":"1year","weight":1.5582},{"period":"ytd","weight":0.7613}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0547},{"period":"6month","weight":0.1989},{"period":"1year","weight":0.1598},{"period":"ytd","weight":0.1341}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035469},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042574},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026843},{"month":8,"riseRate":0.666667,"avgChangeRate":0.010529},{"month":9,"riseRate":0.5,"avgChangeRate":0.028143},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}